Skip to main content

Table 2 Estimated HIV transmissions per 100 cases at 36 months post-infection

From: Efficacy and cost-effectiveness of early antiretroviral therapy and partners’ pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study

Scenario

Month 3

Month 6

Month 12

Month 18

Month 24

Month 36

Sum over 36 months post-infection

Scenarios based on observed data

 Non-ART

2.79(2.05–3.85)

1.41(1.04–1.95)

1.26(0.93–1.74)

1.60(1.18–2.21)

0.71(0.52–0.98)

0.65(0.48–0.90)

41.83(30.75–57.69)

 Standard-ART

1.85(1.36–2.56)

1.77(1.30–2.45)

1.81(1.33–2.50)

0.47(0.34–0.65)

0.44(0.32–0.61)

0.44(0.32–0.61)

32.51(23.89–44.85)

 Early-ART

1.29(0.95–1.78)

0.07(0.05–0.09)

0.03(0.02–0.04)

0.04(0.03–0.06)

0.05(0.04–0.07)

0.26(0.19–0.36)

7.95(5.85–10.95)

Scenarios based on observed and hypothetical data

 Non-ART plus partners’ PrEP

0.28(0.21–0.38)

0.14(0.10–0.19)

0.13(0.09–0.17)

0.16(0.12–0.22)

0.07(0.05–0.10)

0.06(0.05–0.09)

4.18(3.07–5.77)

 Standard-ART plus partners’ PrEP

0.19(0.14–0.26)

0.18(0.13–0.24)

0.18(0.13–0.25)

0.05(0.03–0.06)

0.04(0.03–0.06)

0.04(0.03–0.06)

3.25(2.39–4.48)

 Early-ART plus partners’ PrEP

0.13(0.10–0.18)

0.01(0.01–0.01)

0.01(0.01–0.01)

0.01(0.01–0.01)

0.01(0.01–0.01)

0.03(0.02–0.04)

0.79(0.58–1.09)

  1. ART antiretroviral therapy, PrEP pre-exposure prophylaxis